Skip to content

Investors Overview

Esperion is a pharmaceutical company passionately committed to developing and commercializing non-statin, once-daily, oral therapies to lower elevated low-density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies. Bempedoic acid is being developed as a once-daily, oral inhibitor of ATP Citrate Lyase (ACL), and is designed to bring a targeted mechanism of action to address patients’ unmet medical needs.

Esperion has been a publicly traded company since 2013 and is listed on the NASDAQ Global Select Market under the symbol ESPR.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

Date Title and Summary
Toggle Summary Esperion to Participate in Two Upcoming Virtual Investor Conferences
ANN ARBOR, Mich., May 24, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that members of Esperion management will participate in two upcoming virtual conferences during the month of June. Event:   Jefferies Virtual Healthcare Conference Date:   June 1, 2021 Format:   Fireside
Toggle Summary ESPERION Appoints Sheldon Koenig as President and CEO
-- Mr. Koenig has 30 years of commercial and operational experience as an accomplished leader in the cardiovascular space;  previously served as ESPERION COO -- -- Succeeds Tim Mayleben, who served as President and CEO for almost a decade and will continue to serve as a senior advisor – ANN ARBOR,
Toggle Summary Simulation Model based on Pooled Phase 3 Data Demonstrating NEXLETOL® (bempedoic acid) Tablet’s Potential to Lower Absolute Cardiovascular Event Risk Presented at ACC.21
- Patients with atherosclerotic cardiovascular disease (ASCVD) on maximally tolerated statins and treated with NEXLETOL predicted to experience a 3.3% further absolute reduction in 10-year cardiovascular event risk compared with statins alone (p
Toggle Summary Esperion to Participate in Two Upcoming Virtual Investor Conferences
ANN ARBOR, Mich., May 06, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that members of Esperion management will participate in two upcoming virtual conferences during the month of May. Event: Bank of America 2021 Healthcare Conference Date: May 13, 2021 Format: Presentation &
Toggle Summary ESPERION Reports First Quarter 2021 Financial Results and Provides Company Update
– U.S. Product Revenue of $6.4 Million, Growing Demand Offset by Lower Net Price – – Prescriptions Grew 46% Sequentially; More Than 35,000 Patients now on NEXLETOL ® (bempedoic acid) Tablets and NEXLIZET ® (bempedoic acid and ezetimibe) Tablets – – Secured Major Medicare Part D Contract Covering